0000000001189747

AUTHOR

M. Miller

showing 6 related works from this author

Internationales Komplement Symposion 14. und 15. Juli 1969 in Mainz

1969

Microbiology (medical)media_common.quotation_subjectImmunologyImmunology and AllergyLibrary scienceGeneral MedicineArtmedia_commonZeitschrift für Medizinische Mikrobiologie und Immunologie
researchProduct

IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

2017

0301 basic medicinebusiness.industryMelanomaMutantPhases of clinical researchHematologyFirst in humanmedicine.disease03 medical and health sciences030104 developmental biologyOncologyCancer researchMedicinebusinessAnnals of Oncology
researchProduct

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

1999

Hereditary papillary renal carcinoma (HPRC) is characterized by multiple, bilateral papillary renal carcinomas. Previously, we demonstrated missense mutations in the tyrosine kinase domain of the MET proto-oncogene in HPRC and a subset of sporadic papillary renal carcinomas. In this study, we screened a large panel of sporadic papillary renal carcinomas and various solid tumors for mutations in the MET proto-oncogene. Summarizing these and previous results, mutations of the MET proto-oncogene were detected in 17/129 sporadic papillary renal carcinomas but not in other solid tumors. We detected five novel missense mutations; three of five mutations were located in the ATP-binding region of t…

AdenomaModels MolecularCancer ResearchProtein ConformationDNA Mutational AnalysisMolecular Sequence DataHereditary Papillary Renal Cell CarcinomaBiologymedicine.disease_causeTransfectionProto-Oncogene MasReceptor tyrosine kinaseMiceAdenosine TriphosphateNeoplastic Syndromes HereditaryProto-OncogenesGeneticsCarcinomamedicineMissense mutationAnimalsHumansPoint MutationAmino Acid SequencePhosphorylationCodonMolecular BiologyKidneyMutationBinding SitesSequence Homology Amino AcidPoint mutation3T3 CellsDNA NeoplasmProto-Oncogene Proteins c-metmedicine.diseaseCarcinoma PapillaryKidney NeoplasmsNeoplasm Proteinsmedicine.anatomical_structureCell Transformation NeoplasticCancer researchbiology.proteinMutagenesis Site-DirectedTyrosine kinaseProtein Processing Post-TranslationalSequence AlignmentOncogene
researchProduct

Abstracts of presentations on plant protection issues at the fifth international Mango Symposium Abstracts of presentations on plant protection issue…

1997

0106 biological sciencesZucchini yellow mosaic virusBarley stripe mosaic virusbiologyEcology (disciplines)Plant ScienceCoat proteinbiology.organism_classification01 natural sciencesCucumber mosaic virus010602 entomologyInsect ScienceInternational congressBotany010606 plant biology & botanyPhytoparasitica
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Direct measurement of the W boson width

2009

We present a direct measurement of the width of the W boson using the shape of the transverse mass distribution of W->enu candidates selected in 1 fb-1 of data collected with the D0 detector at the Fermilab Tevatron collider in ppbar collisions at sqrt{s}=1.96 TeV. We use the same methods and data sample that were used for our recently published W boson mass measurement, except for the modeling of the recoil, which is done with a new method based on a recoil library. Our result, 2.028 +- 0.072 GeV, is in agreement with the predictions of the standard model.

Particle physicsTevatronGeneral Physics and AstronomyFOS: Physical sciences= 1.8 TEVElementary particle01 natural sciencesHigh Energy Physics - ExperimentStandard Modellaw.inventionNuclear physicsCOLLIDERParticle decayHigh Energy Physics - Experiment (hep-ex)Physics and Astronomy (all)RecoilRATIOPBARP COLLISIONSlaw0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]RADIATIVE-CORRECTIONSFermilabCollider010306 general physicsNuclear ExperimentBosonPhysics010308 nuclear & particles physicsComputer Science::Information Retrieval14.70.Fm 13.38.Be 13.85.QkTransverse mass= 1.8 TEV; PBARP COLLISIONS; RADIATIVE-CORRECTIONS; RATIO; COLLIDER; DECAYHigh Energy Physics::ExperimentCollider Detector at FermilabDECAY
researchProduct